while the 36-month beta value is 1.22.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The average price point forecasted by analysts for Adamis Pharmaceuticals Corporation (ADMP) is $105.00, The public float for ADMP is 2.01M, and currently, short sellers hold a 0.87% ratio of that floaft. The average trading volume of ADMP on May 26, 2023 was 40.35K shares.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
ADMP) stock’s latest price update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)’s stock price has decreased by -6.40 compared to its previous closing price of 2.50. However, the company has seen a -33.14% decrease in its stock price over the last five trading sessions.
ADMP’s Market Performance
Adamis Pharmaceuticals Corporation (ADMP) has seen a -33.14% fall in stock performance for the week, with a -58.58% decline in the past month and a -87.31% plunge in the past quarter. The volatility ratio for the week is 22.46%, and the volatility levels for the past 30 days are at 17.20% for ADMP. The simple moving average for the last 20 days is -49.85% for ADMP stock, with a simple moving average of -81.84% for the last 200 days.
ADMP Trading at -62.38% from the 50-Day Moving Average
After a stumble in the market that brought ADMP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.87% of loss for the given period.
Volatility was left at 17.20%, however, over the last 30 days, the volatility rate increased by 22.46%, as shares sank -60.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -72.92% lower at present.
During the last 5 trading sessions, ADMP fell by -34.57%, which changed the moving average for the period of 200-days by -91.18% in comparison to the 20-day moving average, which settled at $4.49. In addition, Adamis Pharmaceuticals Corporation saw -80.25% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ADMP
Current profitability levels for the company are sitting at:
- -526.88 for the present operating margin
- -60.93 for the gross margin
The net margin for Adamis Pharmaceuticals Corporation stands at -550.86. The total capital return value is set at -190.80, while invested capital returns managed to touch -204.89. Equity return is now at value -424.00, with -148.50 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 1.19, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 1.36 and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.81.
Conclusion
In a nutshell, Adamis Pharmaceuticals Corporation (ADMP) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
